Related Experiment Video

Updated: May 19, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)

R A Pazo-Cid1, M Lanzuela, G Esquerdo

  • 1Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain. rapazocid@seom.org

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|August 3, 2012
PubMed

Insights

Targeted antiangiogenic drugs show promise for advanced hepatocellular carcinoma. Overcoming resistance to these therapies and identifying novel biomarkers are crucial for improving treatment efficacy.

Area of Science:

  • Oncology
  • Vascular Biology

Background:

  • Angiogenesis is critical in hepatocarcinogenesis.
  • Sorafenib is a targeted therapy for advanced hepatocellular carcinoma.
  • New antiangiogenic drugs show promise in early trials.

Purpose of the Study:

  • Evaluate the safety and efficacy of novel antiangiogenic targeted drugs.
  • Address the urgent need for strategies to overcome resistance to antiangiogenic therapy.
  • Explore the potential of novel biomarkers to enhance drug efficacy.

Main Methods:

  • Phase II trials assessed safety and efficacy of monoclonal antibodies and tyrosine kinase inhibitors.
  • Phase III trials are ongoing for first- and second-line treatment settings.
  • Research is focused on identifying biomarkers for improved therapeutic outcomes.

Main Results:

  • Phase II trials indicate safety and effectiveness of new antiangiogenic agents.
  • Ongoing Phase III trials will provide further insights into treatment efficacy.
  • The development of novel biomarkers is a key area of investigation.

Conclusions:

  • Antiangiogenic targeted drugs represent a significant advancement in treating advanced hepatocellular carcinoma.
  • Overcoming resistance and utilizing biomarkers are essential for optimizing antiangiogenic therapy.
  • Further research is needed to fully elucidate the role of novel biomarkers and resistance mechanisms.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...